Immune System News and Research

RSS

Immunotherapy reshapes immune cell interactions in melanoma-affected lymph nodes

A new study from Mayo Clinic suggests checkpoint immunotherapy may reshape the immune environment within lymph nodes after melanoma has spread to them.

30 Oct 2026

Myeloid immune cells play key roles in aortic health and disease

The aorta is often viewed primarily as the body's largest blood vessel-a durable conduit that delivers oxygen-rich blood from the heart to every organ.

30 Oct 2026

Hyperactive cancer-promoting proteins help tumor cells evade immune attack

The immune system may recognize a cancer cell and still fail to destroy it. Researchers at Hiroshima University and their international collaborators found that hyperactive YAP and TAZ (YAP/TAZ), two cancer-promoting proteins, were associated with genomic instability that may make cancer cells more recognizable to the immune system, while also increasing PD-L2, which helps the cells suppress T-cell attack.

30 Oct 2026

Targeting specific enzyme reverses radiation-induced immune suppression in cancer

Researchers at the University of Chicago identified a mechanism to make immune cells reprogrammed by radiation therapy attack tumors rather than protect them.

30 Oct 2026

Targeting ANO6 protein weakens pancreatic cancer and boosts immunity

Fox Chase Cancer Center researchers identified a potential therapeutic target for pancreatic cancer after showing that tumor growth can be slowed and immune suppression can be reduced in preclinical trials by blocking a particular protein, called anoctamin 6 (ANO6).

30 Oct 2026

Gut microbial catalog reveals systemic inflammation drivers in spinal injury

Scientists exploring the links between a spinal cord injury, inflammation and immune function have turned their attention to a genome-level analysis of the gut microbial community, with early study results offering hints at potential new approaches to aid healing.

30 Oct 2026

Platelet hyperactivity drives glioblastoma progression and deep vein thrombosis

New Cleveland Clinic research published in Cancer Cell shows that people with glioblastoma have more active platelets, which are cells involved in blood clotting. Platelets also communicate with other cells and can influence immune activity. The overactive platelets in people with glioblastoma slow the activity of cancer-fighting T cells, which can contribute to tumor growth and cancer progression.

30 Oct 2026

Brief dietary changes may prime the immune system for inflammation

Scientists have long known that diet shapes the immune system. Now, a UC San Francisco team has found that even a brief dietary change can substantially change how the body responds to skin irritation, at least in mice.

29 Oct 2026

Large genetic study uncovers new risk factors for Alzheimer's

A large-scale international study, led by Ole Andreassen at University of Oslo and Oslo University Hospital, in collaboration with international consortium, offers new insights for understanding the disease and developing future treatments.

29 Oct 2026

New study reveals why colorectal cancer is more aggressive in youth

Dana-Farber Cancer Institute researchers, along with Mass General Brigham researchers from the Gene Lay Institute of Immunology and Inflammation, and the Broad Institute, have uncovered biological clues to why colorectal cancer can behave more aggressively in younger people.

29 Oct 2026

New Yale initiative explores the role of inflammation in disease

Yale School of Medicine (YSM) was awarded a $10 million grant from the Blavatnik Family Foundation (BFF) to launch a new research initiative in the field of inflammation science.

29 Oct 2026

Unraveling the mystery behind lower cancer risks in type 1 diabetes patients

New research in The Journal of Immunology uncovers how high blood sugar (hyperglycemia) and type 1 diabetes (T1D) may protect against certain cancers like melanoma, breast and colon cancer. T1D has been associated with a decreased risk of certain cancers, but the exact reasons why have remained a mystery. New data from studies in mice, now shows that it could be due to changes in immune cells, called T cells, caused by hyperglycemia.

29 Oct 2026

Mutated neutrophils may trigger immune attacks in lupus

Scientists at La Jolla Institute for Immunology (LJI) and the University of Washington (UW) have discovered that patients with lupus have unusual mutations that may turn their bodies into battlegrounds.

28 Oct 2026

COMPASS pathway helps regulatory T cells prevent intestinal inflammation

Trillions of bacteria live in the human gut without triggering an immune response. Scientists at St. Jude Children's Research Hospital have now discovered a gene-regulatory pathway that helps maintain this delicate balance.

28 Oct 2026

Dual-targeting antibody successfully tackles multiple tumor types in mice

A novel antibody therapy empowers the immune system's tumor-fighting capabilities in mice by targeting immune-suppressing T cells with greater precision than previous approaches, according to new work.

28 Oct 2026

Landmark studies map how genetic differences drive human diseases

In three landmark studies published in Nature today, Australian researchers have made major advances in our understanding of how genetic differences between people influence disease.

28 Oct 2026

New research center aims to accelerate hepatitis C vaccine development

The shifty hepatitis C virus (HCV) has a knack for outmaneuvering the immune system. Its secret is an especially high mutation rate, which has generated an abundance of viral variants with extreme genetic diversity.

27 Oct 2026

Vitamin B5 derivative pantethine helps prevent and alleviate psoriasis symptoms in mice

Researchers in China have discovered that the vitamin B5 derivative pantethine limits the activity of immune cells that are key contributors to autoimmune diseases such as psoriasis.

27 Oct 2026

Immunotherapy combination sets a new standard of care for extensive-stage small cell lung cancer

In patients with extensive-stage small cell lung cancer (ES-SCLC), tarlatamab, a bispecific T-cell engager, plus durvalumab as first-line maintenance therapy extended median overall survival by more than eight months, more than tripled progression-free survival, and reduced the risk of death by 58% compared to durvalumab alone, according to results of the phase 3 open-label, multicenter, randomized DeLLphi-305 study, which was presented by Jacob Sands, MD, Associate Chief of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, during the Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain, on Oct. 24.

26 Oct 2026